These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 39181211)

  • 21. Phthalate esters enhance quinolinate production by inhibiting alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase (ACMSD), a key enzyme of the tryptophan pathway.
    Fukuwatari T; Ohsaki S; Fukuoka S; Sasaki R; Shibata K
    Toxicol Sci; 2004 Oct; 81(2):302-8. PubMed ID: 15229365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of hepatic ChREBP⍺-CYP2C50 axis-driven fatty acid oxidation sensitizes mice to diet-induced MASLD/MASH.
    Zhang D; Zhao Y; Zhang G; Lank D; Cooke S; Wang S; Nuotio-Antar A; Tong X; Yin L
    Mol Metab; 2024 Jul; 85():101957. PubMed ID: 38740087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.
    López-Pascual E; Rienda I; Perez-Rojas J; Rapisarda A; Garcia-Llorens G; Jover R; Castell JV
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
    Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
    Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Choline-deficient, high-fat diet-induced MASH in Göttingen Minipigs: characterization and effects of a chow reversal period.
    Hvid H; Hjuler ST; Bedossa P; Tiniakos DG; Kamzolas I; Harder LM; Xue Y; Perfield JW; Kirk RK; Latta M; Mikkelsen LF; Pedersen HD;
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G571-G585. PubMed ID: 39041677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective Effects of Hepatocyte Stress Defenders, Nrf1 and Nrf2, against MASLD Progression.
    Akl MG; Li L; Widenmaier SB
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application.
    Longo M; Paolini E; Di Benedetto P; Tomassini E; Meroni M; Dongiovanni P
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Sierra-Cruz M; Lambertos A; Rico-Chazarra S; Oliva-Bolarín A; Balaguer-Román A; Yuste JE; Martínez CM; Mika A; Frutos MD; Llamoza-Torres CJ; Córdoba-Chacón J; Ramos-Molina B
    J Pathol; 2024 Sep; 264(1):101-111. PubMed ID: 39022853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
    ; ;
    Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19.
    Jacobs AK; Morley SD; Samuel K; Morgan K; Boswell L; Kendall TJ; Dorward DA; Fallowfield JA; Hayes PC; Plevris JN
    World J Gastroenterol; 2024 Aug; 30(31):3705-3716. PubMed ID: 39192998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.
    Marti-Aguado D; Calleja JL; Vilar-Gomez E; Iruzubieta P; Rodríguez-Duque JC; Del Barrio M; Puchades L; Rivera-Esteban J; Perelló C; Puente A; Gomez-Medina C; Escudero-García D; Serra MA; Bataller R; Crespo J; Arias-Loste MT
    J Hepatol; 2024 Jul; ():. PubMed ID: 38971533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic NLRP3-Derived Hsp70 Binding to TLR4 Mediates MASLD to MASH Progression upon Inhibition of PP2A by Harmful Algal Bloom Toxin Microcystin, a Second Hit.
    Roy S; Saha P; Bose D; Trivedi A; More M; Xiao S; Diehl AM; Chatterjee S
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The lipopolysaccharide-TLR4 axis regulates hepatic glutaminase 1 expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis.
    Mercado-Gómez M; Goikoetxea-Usandizaga N; Kerbert AJC; Gracianteparaluceta LU; Serrano-Maciá M; Lachiondo-Ortega S; Rodriguez-Agudo R; Gil-Pitarch C; Simón J; González-Recio I; Fondevila MF; Santamarina-Ojeda P; Fraga MF; Nogueiras R; Heras JL; Jalan R; Martínez-Chantar ML; Delgado TC
    Metabolism; 2024 Sep; 158():155952. PubMed ID: 38906371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AKR1B1 drives hyperglycemia-induced metabolic reprogramming in MASLD-associated hepatocellular carcinoma.
    Syamprasad NP; Jain S; Rajdev B; Panda SR; Kumar GJ; Shaik KM; Shantanu PA; Challa VS; Jorvekar SB; Borkar RM; Vaidya JR; Tripathi DM; Naidu VGM
    JHEP Rep; 2024 Feb; 6(2):100974. PubMed ID: 38283757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).
    Vacca M; Kamzolas I; Harder LM; Oakley F; Trautwein C; Hatting M; Ross T; Bernardo B; Oldenburger A; Hjuler ST; Ksiazek I; Lindén D; Schuppan D; Rodriguez-Cuenca S; Tonini MM; Castañeda TR; Kannt A; Rodrigues CMP; Cockell S; Govaere O; Daly AK; Allison M; Honnens de Lichtenberg K; Kim YO; Lindblom A; Oldham S; Andréasson AC; Schlerman F; Marioneaux J; Sanyal A; Afonso MB; Younes R; Amano Y; Friedman SL; Wang S; Bhattacharya D; Simon E; Paradis V; Burt A; Grypari IM; Davies S; Driessen A; Yashiro H; Pors S; Worm Andersen M; Feigh M; Yunis C; Bedossa P; Stewart M; Cater HL; Wells S; Schattenberg JM; Anstee QM; ; Tiniakos D; Perfield JW; Petsalaki E; Davidsen P; Vidal-Puig A
    Nat Metab; 2024 Jun; 6(6):1178-1196. PubMed ID: 38867022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time-of-day-dependent variation of the human liver transcriptome and metabolome is disrupted in MASLD.
    Johanns M; Haas JT; Raverdy V; Vandel J; Chevalier-Dubois J; Guille L; Derudas B; Legendre B; Caiazzo R; Verkindt H; Gnemmi V; Leteurtre E; Derhourhi M; Bonnefond A; Froguel P; Eeckhoute J; Lassailly G; Mathurin P; Pattou F; Staels B; Lefebvre P
    JHEP Rep; 2024 Jan; 6(1):100948. PubMed ID: 38125300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repurposing of the analgesic Neurotropin for MASLD/MASH treatment.
    Tsuchiya T; Kim SY; Matsuda M; Kim J; Stotland A; Naiki M; Seki E
    Hepatol Commun; 2024 Aug; 8(8):. PubMed ID: 39023282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Down-regulation of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase by polyunsaturated fatty acids in hepatocytes is not mediated by PPARalpha.
    Sasaki N; Egashira Y; Sanada H
    Eur J Nutr; 2008 Mar; 47(2):80-6. PubMed ID: 18320257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.